Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy

Yumi Aoyama, Chie Moriya, Koji Kamiya, Miki Nagai, David Rubenstein, Keiji Iwatsuki, Yasuo Kitajima

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

High-dose intravenous immunoglobulin (HD-IVIg) has several distinguishing therapeutic characteristics. However, a certain number of pemphigus cases have been experienced, which did not respond to HDIVIg. This is the first case report that the serum level of anti-desmoglein (Dsg) 1 antibody rebounded, critically associated with IgG serum level. We describe a patient with pemphigus foliaceus (PF), unresponsive to oral prednisolone followed by pulse therapy and double-filtration plasmapheresis, in whom clinical remission was induced by 4 courses of HD-IVIg. Anti-Dsg1 antibody levels, serum IgG and disease activity were monitored. Anti-Dsg1 antibody titers rapidly decreased after IVIg treatment when total IgG levels were high; however, the serum level of anti-Dsg1 antibody rebounded as the total IgG level returned to normal. The levels of anti-Dsg1 antibody were decreased for an average of 13.7 days after treatment. The therapeutic effect of IVIg treatmentwas associated with an increased serum level of total IgG. IVIg therapy reduced the titers of autoantibody by accelerating the catabolism of immunoglobulin induced by high IgG serum levels. IVIg itself appears to accelerate IgG degradation rather than suppress IgG production. Sufficient suppression of antibody production is critical for successful treatment with IVIg.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalEuropean Journal of Dermatology
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Pemphigus
Autoantibodies
Immunoglobulin G
Anti-Idiotypic Antibodies
Serum
Intravenous Immunoglobulins
Therapeutics
Desmoglein 1
Plasmapheresis
Therapeutic Uses
Prednisolone
Antibody Formation
Immunoglobulins
Antibodies

Keywords

  • Desmoglein
  • High-dose intravenous immunoglobulin
  • Pemphigus

ASJC Scopus subject areas

  • Dermatology

Cite this

Aoyama, Y., Moriya, C., Kamiya, K., Nagai, M., Rubenstein, D., Iwatsuki, K., & Kitajima, Y. (2011). Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. European Journal of Dermatology, 21(1), 58-61. https://doi.org/10.1684/ejd.2010.1169

Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. / Aoyama, Yumi; Moriya, Chie; Kamiya, Koji; Nagai, Miki; Rubenstein, David; Iwatsuki, Keiji; Kitajima, Yasuo.

In: European Journal of Dermatology, Vol. 21, No. 1, 01.2011, p. 58-61.

Research output: Contribution to journalArticle

Aoyama, Y, Moriya, C, Kamiya, K, Nagai, M, Rubenstein, D, Iwatsuki, K & Kitajima, Y 2011, 'Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy', European Journal of Dermatology, vol. 21, no. 1, pp. 58-61. https://doi.org/10.1684/ejd.2010.1169
Aoyama Y, Moriya C, Kamiya K, Nagai M, Rubenstein D, Iwatsuki K et al. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. European Journal of Dermatology. 2011 Jan;21(1):58-61. https://doi.org/10.1684/ejd.2010.1169
Aoyama, Yumi ; Moriya, Chie ; Kamiya, Koji ; Nagai, Miki ; Rubenstein, David ; Iwatsuki, Keiji ; Kitajima, Yasuo. / Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy. In: European Journal of Dermatology. 2011 ; Vol. 21, No. 1. pp. 58-61.
@article{363f3d83df654b2686d2f4d3f01b251b,
title = "Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy",
abstract = "High-dose intravenous immunoglobulin (HD-IVIg) has several distinguishing therapeutic characteristics. However, a certain number of pemphigus cases have been experienced, which did not respond to HDIVIg. This is the first case report that the serum level of anti-desmoglein (Dsg) 1 antibody rebounded, critically associated with IgG serum level. We describe a patient with pemphigus foliaceus (PF), unresponsive to oral prednisolone followed by pulse therapy and double-filtration plasmapheresis, in whom clinical remission was induced by 4 courses of HD-IVIg. Anti-Dsg1 antibody levels, serum IgG and disease activity were monitored. Anti-Dsg1 antibody titers rapidly decreased after IVIg treatment when total IgG levels were high; however, the serum level of anti-Dsg1 antibody rebounded as the total IgG level returned to normal. The levels of anti-Dsg1 antibody were decreased for an average of 13.7 days after treatment. The therapeutic effect of IVIg treatmentwas associated with an increased serum level of total IgG. IVIg therapy reduced the titers of autoantibody by accelerating the catabolism of immunoglobulin induced by high IgG serum levels. IVIg itself appears to accelerate IgG degradation rather than suppress IgG production. Sufficient suppression of antibody production is critical for successful treatment with IVIg.",
keywords = "Desmoglein, High-dose intravenous immunoglobulin, Pemphigus",
author = "Yumi Aoyama and Chie Moriya and Koji Kamiya and Miki Nagai and David Rubenstein and Keiji Iwatsuki and Yasuo Kitajima",
year = "2011",
month = "1",
doi = "10.1684/ejd.2010.1169",
language = "English",
volume = "21",
pages = "58--61",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "John Libbey Eurotext",
number = "1",

}

TY - JOUR

T1 - Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy

AU - Aoyama, Yumi

AU - Moriya, Chie

AU - Kamiya, Koji

AU - Nagai, Miki

AU - Rubenstein, David

AU - Iwatsuki, Keiji

AU - Kitajima, Yasuo

PY - 2011/1

Y1 - 2011/1

N2 - High-dose intravenous immunoglobulin (HD-IVIg) has several distinguishing therapeutic characteristics. However, a certain number of pemphigus cases have been experienced, which did not respond to HDIVIg. This is the first case report that the serum level of anti-desmoglein (Dsg) 1 antibody rebounded, critically associated with IgG serum level. We describe a patient with pemphigus foliaceus (PF), unresponsive to oral prednisolone followed by pulse therapy and double-filtration plasmapheresis, in whom clinical remission was induced by 4 courses of HD-IVIg. Anti-Dsg1 antibody levels, serum IgG and disease activity were monitored. Anti-Dsg1 antibody titers rapidly decreased after IVIg treatment when total IgG levels were high; however, the serum level of anti-Dsg1 antibody rebounded as the total IgG level returned to normal. The levels of anti-Dsg1 antibody were decreased for an average of 13.7 days after treatment. The therapeutic effect of IVIg treatmentwas associated with an increased serum level of total IgG. IVIg therapy reduced the titers of autoantibody by accelerating the catabolism of immunoglobulin induced by high IgG serum levels. IVIg itself appears to accelerate IgG degradation rather than suppress IgG production. Sufficient suppression of antibody production is critical for successful treatment with IVIg.

AB - High-dose intravenous immunoglobulin (HD-IVIg) has several distinguishing therapeutic characteristics. However, a certain number of pemphigus cases have been experienced, which did not respond to HDIVIg. This is the first case report that the serum level of anti-desmoglein (Dsg) 1 antibody rebounded, critically associated with IgG serum level. We describe a patient with pemphigus foliaceus (PF), unresponsive to oral prednisolone followed by pulse therapy and double-filtration plasmapheresis, in whom clinical remission was induced by 4 courses of HD-IVIg. Anti-Dsg1 antibody levels, serum IgG and disease activity were monitored. Anti-Dsg1 antibody titers rapidly decreased after IVIg treatment when total IgG levels were high; however, the serum level of anti-Dsg1 antibody rebounded as the total IgG level returned to normal. The levels of anti-Dsg1 antibody were decreased for an average of 13.7 days after treatment. The therapeutic effect of IVIg treatmentwas associated with an increased serum level of total IgG. IVIg therapy reduced the titers of autoantibody by accelerating the catabolism of immunoglobulin induced by high IgG serum levels. IVIg itself appears to accelerate IgG degradation rather than suppress IgG production. Sufficient suppression of antibody production is critical for successful treatment with IVIg.

KW - Desmoglein

KW - High-dose intravenous immunoglobulin

KW - Pemphigus

UR - http://www.scopus.com/inward/record.url?scp=79957445862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957445862&partnerID=8YFLogxK

U2 - 10.1684/ejd.2010.1169

DO - 10.1684/ejd.2010.1169

M3 - Article

VL - 21

SP - 58

EP - 61

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 1

ER -